Default company panoramic image

Refer2Input, LLC (R2i)

Refer2Input provides a novel platform that revolutionizes the capability and utility of bioelectric signal monitoring and processing.

  • Stage Concept Only
  • Industry Biotechnology
  • Location Indianapolis, IN, USA
  • Currency USD
  • Founded February 2013
  • Employees 2

Company Summary

Pioneering the realm of biosystem dynamics, Refer2Input (R2i) offers a revolutionary bioelectric recording platform. The flexibility and efficiency provided by R2i's patent pending technology provides both clinicians and scientists an innovative tool to diagnose pathologies, investigate physiological mechanisms and develop novel interventions aimed at neural and musculoskeletal disorders (e.g., Parkinson’s, MS, Huntington's, stroke rehab, pain).


  • Default avatar
    Ken Yoshida

    Dr. Yoshida has spent nearly 20 years researching methods to restore sensory-motor function to those with neuromuscular disorders and injuries. He has developed novel neuroprosthetic and myoelectric devices and interfaces as tools to investigate the information flow within the nervous system. Investigating neural data streams across multiple bioelectric interfaces, his work has been funded at the national and international levels.

  • Default avatar
    William Combs
    Scientific Advisor

    Mr. Combs has almost 30 years’ experience in the research and development of therapies and diagnostics of implanted cardiac pacemakers, defibrillators and subcutaneously implanted monitors. Having led Medtronic’s research investigations in the use of bio-impedance measurements in addition to the algorithm development and systems design for implanted pacemakers and defibrillators, he is well versed in bioelectric technologies.

  • Default avatar
    Joe Trebley
    Business Manager

    Dr. Trebley’s experiences in venture capital, biotech and tech transfer uniquely qualify him to provide early-stage support to R2i in conjunction with IURTC and the Spin Up Program. Throughout his career, he has raised over $2.5 M in equity financing along with over $2 M in non-dilutive state and federal grant funding in addition to initiating and managing two partnership deals with large (greater than $50 B market cap) pharmaceutical companies.


  • Default avatar
    Jim Schulz